What's Happening Right Now

Seven amicus briefs landed at the U.S. Supreme Court in June 2026 - all supporting Google's petition to eliminate the Patent Trial and Appeal Board's Settled Expectations doctrine. The filers include the Computer & Communications Industry Association (CCIA), the High Tech Inventors Alliance (HTIA), the Alliance for Automotive Innovation, Unified Patents LLC, the PTAB Bar Association, the Association for Accessible Medicines (AAM), and a coalition of 35 intellectual property law professors. Computer and automotive industry groups are backing the challenge, calling the doctrine an ultra vires overreach by the USPTO that has quietly killed hundreds of legitimate patent challenges.

Importantly, if SCOTUS grants certiorari, the outcome will reshape how companies mount invalidity challenges against patents that have been in force for six or more years. That is a significant slice of the active patent landscape - and a direct concern for any IP team managing litigation risk.

What Is the Settled Expectations Doctrine?

Introduced under recent USPTO administration policy, the Settled Expectations doctrine allows the PTAB to deny institution of an IPR petition on the grounds that a patent owner has developed a reasonable reliance interest in their patent's validity - simply because the patent has been around long enough.

Specifically, the doctrine was formalized when the USPTO designated two precedential decisions on January 9, 2026: Dabico Inc. v. AXA Power ApS, IPR2025-00408 (PTAB June 18, 2025), which denied institution outright on settled-expectations grounds, and Amgen Inc. v. Bristol-Myers Squibb Co., IPR2025-00601 (PTAB July 24, 2025), which extended the doctrine's reach to patents as young as three years.

The underlying vehicle at the Supreme Court is Google LLC v. VirtaMove Corp. (U.S. Pat. No. 7,519,814), where the Federal Circuit declined to grant mandamus relief in January 2026 against a PTAB denial of Google's IPR petition on a patent then 14 years in force.

In practice, this creates an informal six-year safe harbor. Once a patent crosses that threshold, challengers face a dramatically higher bar to get an IPR instituted, regardless of the strength of their prior art.

The Numbers Are Stark

The numbers are stark:

770 IPR and PGR petitions have been denied on discretionary grounds since the new timing rules took effect in March 2025 (IPWatchdog, June 2026)

201 of those denials are directly attributable to the Settled Expectations doctrine - making it the single largest cause of IPR denial, ahead of parallel-litigation (Fintiv) and follow-on petition (General Plastic) grounds (IPWatchdog, June 2026)

The doctrine now ranks as the leading single cause of IPR denial

Why Industry Is Pushing Back

Specifically, the amicus coalition - spanning tech, automotive, and manufacturing sectors - argues the doctrine has no statutory basis. The America Invents Act authorizes the USPTO to institute IPR petitions based on the merits of the prior art presented. Nowhere does the statute permit denial based on how long a patent owner has held their patent.

A Two-Tier Patent System

The practical effect is a two-tier patent system:

Young patents

Remain challengeable at the PTAB through the standard IPR institution process based on prior art merits.

Mature patents

Often the most commercially significant and most widely asserted - receive de facto immunity from the most efficient invalidity mechanism available.

For defendants in patent litigation, particularly those in jurisdictions without favorable venue options, PTAB has historically been the fastest and most cost-effective path to killing a weak patent. The Settled Expectations doctrine erodes that option precisely when it matters most.

What the Corpus Data Shows

Using IP Author's live corpus of 179 million global patent publications (June 2026 snapshot), we queried all currently active US patent families to map the settled expectations exposure window. The results are not theoretical.

Notably, active US patent families in corpus: 45,644,971. Of those, approximately 16.8 million - nearly 37% - carry a priority date before June 2020, placing them squarely inside the six-year threshold where the doctrine currently operates. High-citation assets (20 or more forward citations) with pre-2020 priority run into the millions: these are the most-asserted, most commercially significant patents, and the ones the doctrine shields most effectively.

Sector Concentration

Sector concentration is sharpest where product cycles are longest. There are 1,283,672 active US pharmaceutical and medical-device patent families (CPC A61), 1,690,196 in telecommunications (CPC H04), 740,258 in vehicles and automotive systems (CPC B60), and 406,100 in semiconductors (CPC H01L) - all areas where it is routine for a product to reach market well after the six-year clock has run.

The table below shows the priority-year distribution of all 45.6 million currently active US patent families. Everything at 2019 and earlier is, under the current doctrine, presumptively shielded from IPR challenge.

Priority Year Active US Patent Families IPR Status Under Doctrine
20251,452,878Challengeable (< 1 yr)
20243,949,487Challengeable (< 2 yrs)
20234,622,818Challengeable (< 3 yrs)
20223,980,391Challengeable (< 4 yrs)
20213,495,820Challengeable (< 5 yrs)
20203,164,010Challengeable (< 6 yrs)
20192,464,056RISK ZONE - Settled Expectations
20182,007,918RISK ZONE - Settled Expectations
20171,598,382RISK ZONE - Settled Expectations
20161,307,369RISK ZONE - Settled Expectations
2015973,022RISK ZONE - Settled Expectations
2014846,110RISK ZONE - Settled Expectations
2013775,484RISK ZONE - Settled Expectations
2012680,132RISK ZONE - Settled Expectations
2011566,442RISK ZONE - Settled Expectations
2010541,215RISK ZONE - Settled Expectations
Pre-2010~5,100,000+RISK ZONE - Settled Expectations
TOTAL PRE-2020~16,800,000+Approx. 37% of all active US patents

Source: IP Author patent corpus, 179M global publications, June 2026. Family-deduplicated counts (one row per extended patent family). Active status per live legal-status feed.

Key finding

A substantial portion have priority dates older than six years - placing them squarely in the settled expectations risk zone under the current doctrine. Technology areas with long product development cycles - pharmaceuticals, semiconductors, automotive - face the greatest concentration of mature, high-value patents that challengers can no longer reach via IPR.

Settled Expectations Exposure Audit Checklist

Download this checklist to run a structured exposure audit on your patent portfolio. Enter your work email below to receive the PDF directly - it takes under two minutes to complete and covers the six highest-impact risk categories.

Six-Category Risk Assessment

Section 1 - Identify At-Risk Patents
List all active US patents asserted against your company (or likely to be).
Flag any with a priority date on or before June 15, 2020 (exactly 6 years ago today).
Flag any where IPR would be the primary invalidity vehicle (no strong §101 or §112 defense).
Section 2 - Assess Exposure by Sector
Identify the CPC class of each at-risk patent (pharma/A61, automotive/B60, telecom/H04, semiconductor/H01L).
Note whether the patent owner operates in a sector with long product cycles (most exposure).
Check whether the patent has 20 or more forward citations (high-assertion-risk indicator).
Section 3 - IPR Window Status
Confirm whether an IPR petition has already been filed on this patent.
If not, calculate days remaining before the one-year bar (35 U.S.C. § 315(b)) if litigation is pending.
Record current PTAB institution rate (now ~35%, down from ~75% pre-doctrine).
Section 4 - Prior Art Readiness
Confirm a prior art search has been run across non-English and non-US sources.
Verify that identified references predate the challenged patent's priority date.
Rate the strength of your best reference: anticipatory (§102) or obviousness combination (§103).
Section 5 - Parallel Strategy
Identify district court venues where invalidity can be raised if IPR is denied.
Assess whether ex parte reexamination is viable as a fallback.
Model licensing leverage change if SCOTUS rules for Google in Google LLC v. VirtaMove Corp.
Section 6 - SCOTUS Watch
Confirm whether Google LLC v. VirtaMove Corp. (cert petition filed April 27, 2026) has received cert grant.
If cert granted, set calendar alert for oral argument date and potential ruling window (Oct 2026 - June 2027 term).
Pre-build invalidity case for highest-risk patents so your team moves immediately on a favorable ruling.

Three Things Your IP Team Should Do Now

1. Identify At-Risk Patents in Your Docket

Identify active patents asserted against you - or likely to be asserted - that are approaching or have passed the six-year threshold. These are the assets where the PTAB door is either closing or already closed under the current doctrine. Time-limited IPR windows require early action.

2. Build Litigation-Ready Prior Art Now

Additionally, with PTAB access uncertain for older patents, district court invalidity arguments become more important. Invest now in deep prior art searches that are litigation-ready - not just prosecution-quality. IP Author's Prior Art search surfaces invalidating references across 178M global publications, including non-English prior art that US-only searches routinely miss.

3. Watch the SCOTUS Docket

If SCOTUS grants cert on Google's petition, the procedural landscape at the PTAB could shift quickly. A ruling that the doctrine exceeds statutory authority would reopen the IPR path to hundreds of currently-shielded patents. IP teams that have already built their invalidity cases will move fastest.

What Happens If SCOTUS Rules for Google?

A favorable ruling would likely reinstate full merits-based IPR institution review - meaning the PTAB would be required to evaluate petitions on prior art quality, not patent age. This would:

Potential outcomes of a Google win
✓ Unlock IPR challenges against thousands of mature patents currently insulated by the doctrine.
✓ Reset negotiating leverage in licensing disputes where patent holders have relied on IPR-immunity as a backstop.
✓ Increase PTAB filing volume significantly, particularly from defendants in ongoing litigation.

Therefore, patent owners with large portfolios of older, high-value patents should model the exposure now - not after a ruling.

The Bigger Picture: IPR Is Still Your Best Tool

Despite the doctrine's chilling effect, inter partes review remains the most cost-efficient patent invalidity mechanism in the US system. Average IPR costs run a fraction of district court litigation, with faster timelines and a lower burden of proof for prior art challenges.

In fact, the current uncertainty is not a reason to abandon IPR strategy - it is a reason to execute it earlier, more precisely, and with better prior art intelligence than your opponent.

IP Author's prosecution intelligence tools give your team the same data advantage that the largest patent law firms use: real-time filewrapper access, examiner analytics, and prior art search across a corpus that covers every major patent office on the planet.

Stay Ahead of the PTAB

Ultimately, the Settled Expectations doctrine may not survive SCOTUS scrutiny. But whether it does or does not, the IP teams that win are the ones who plan for both outcomes today.


Sources: Patently-O (June 2026), IPWatchdog (June 2026), Law360 Patent Policy Watch 2026, IP Author patent corpus (178M global publications, June 2026 snapshot).